IE 11 is not supported. For an optimal experience visit our site on another browser.
  • Legal analysts weigh in on Alec Baldwin’s charge in 'Rust' shooting

    04:32
  • How authorities captured the suspect in the grisly Idaho murders

    04:32
  • A look back at Ukraine's year of heartbreak and heroism

    04:11
  • Border braces for wave of new migrants with likely end of Title 42

    03:57
  • Brittney Griner swap puts spotlight on other American prisoners

    04:42
  • Now Playing

    Experimental Alzheimer’s drug shows promising results in patients

    04:38
  • UP NEXT

    World Cup puts Qatar’s human rights abuses in spotlight

    04:43
  • Are tech industry layoffs an indication of our economy's future?

    04:24
  • Americans turn out in record numbers to vote in midterm elections

    04:49
  • Political rhetoric threatens violence around midterm elections

    04:50
  • How US cities are sheltering migrants amid border crisis

    05:01
  • How can the Fed tame inflation as prices rise faster than expected?

    04:49
  • Florida residents, insurers face heavy task of rebuilding after Hurricane Ian

    04:57
  • Why women need access to better breast cancer screenings

    04:54
  • How routine anxiety screenings can help American’s mental health

    04:30
  • Can Ukraine’s recent liberations lead to a turning point in the war?

    04:29
  • 21 years later, 9/11's impact on Americans endures

    04:47
  • New report shows negative impact of remote learning on students

    04:36
  • Are we facing a national teacher shortage?

    04:42
  • What does the future hold for the Republican Party?

    04:43

Experimental Alzheimer’s drug shows promising results in patients

04:38

An experimental drug for Alzheimer's was found to reduce cognitive decline in patients significantly, offering a potential breakthrough against the devastating disease. NBC’s Maggie Vespa reports in this week’s Sunday Focus on the risks and how soon the drug might be available.

Chris Hemsworth on learning about his Alzheimer’s risk: ‘It became a wonderful motivator’